Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia

In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligibl...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Saudi medicine 2021-07, Vol.41 (4), p.198-205
Main Authors: Abdrabou, Ahmed Kotb, Sharif, Fahad Al, Fakih, Riad El, Hashmi, Shahrukh, Khafaga, Yasser Mohamed, Alhayli, Saud, Zahrani, Hazaa Al, Ahmed, Syed, Fraih, Feras Al, Shaheen, Marwan, Rasheed, Walid, Chaudhri, Naeem Arshad, Mohareb, Fahad Al, Khalil, Hala, Aljurf, Mahmoud, Hanbali, Amr
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Humans
In Situ Hybridization, Fluorescence
Male
Middle Aged
Multiple Myeloma - drug therapy
Original
Quality of Life
Retrospective Studies
Saudi Arabia - epidemiology
Transplantation, Autologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT. Determine the demographic characteristics of MM patients and the outcomes of ASCT. Retrospective. Tumor registry database of major tertiary cancer care center in Riyadh. We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015. The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS). 169 patients with newly diagnosed MM. The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (
ISSN:0256-4947
0975-4466
DOI:10.5144/0256-4947.2021.198